Marc Brisson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10669626/publications.pdf

Version: 2024-02-01

88 papers	6,672 citations	66343 42 h-index	64796 79 g-index
90 all docs	90 docs citations	90 times ranked	6094 citing authors

#	Article	IF	Citations
1	Now or later: Health impacts of delaying singleâ€dose <scp>HPV</scp> vaccine implementation in a highâ€burden setting. International Journal of Cancer, 2022, 151, 1804-1809.	5.1	4
2	Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 116-126.	9.1	8
3	From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness. Preventive Medicine, 2021, 144, 106354.	3.4	12
4	Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15- to 59-Year-Olds in the United States. Sexually Transmitted Diseases, 2021, 48, 273-277.	1.7	48
5	The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. Sexually Transmitted Diseases, 2021, 48, 278-284.	1.7	11
6	The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018. Sexually Transmitted Diseases, 2021, 48, 215-221.	1.7	68
7	Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine, 2021, 39, 871-875.	3.8	5
8	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2021, 21, 1598-1610.	9.1	34
9	Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. International Journal of Infectious Diseases, 2021, 112, 136-143.	3.3	5
10	Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine, 2020, 38, 1302-1314.	3.8	61
11	Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. Annals of Internal Medicine, 2020, 172, 22.	3.9	60
12	Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet Global Health, 2020, 8, e536-e544.	6.3	39
13	Population-level impact of human papillomavirus vaccination â€“ Authors' reply. Lancet, The, 2020, 395, 412-413.	13.7	0
14	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 575-590.	13.7	421
15	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 591-603.	13.7	321
16	HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg. PeerJ, 2020, 8, e8516.	2.0	1
17	Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Medicine, 2019, 17, 163.	5.5	39
18	An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine, 2019, 37, 4376-4381.	3.8	11

#	Article	IF	Citations
19	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100184.	4.5	41
20	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet, The, 2019, 394, 497-509.	13.7	630
21	Global elimination of cervical cancer as a public health problem. Lancet Oncology, The, 2019, 20, 319-321.	10.7	58
22	2301. Increased Risk of Varicella-Associated Hospitalizations Among Adult Immigrants From Temperate and Tropical Countries After the Introduction of a Childhood Varicella Vaccination Program in Quebec, Canada. Open Forum Infectious Diseases, 2019, 6, S788-S788.	0.9	0
23	Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. Cmaj, 2019, 191, E932-E939.	2.0	14
24	Potential lives saved in 73 countries by adopting multiâ€cohort vaccination of 9â€“14â€yearâ€old girls against human papillomavirus. International Journal of Cancer, 2018, 143, 317-323.	5.1	15
25	Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine, 2018, 36, 4806-4815.	3.8	68
26	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health, 2018, 21, 1250-1258.	0.3	21
27	Evidence of synergistic relationships between <scp>HIV</scp> and Human Papillomavirus (<scp>HPV</scp>): systematic reviews and metaâ€analyses of longitudinal studies of <scp>HPV</scp> acquisition and clearance by <scp>HIV</scp> status, and of <scp>HIV</scp> acquisition by <scp>HPV</scp> status. Journal of the International AIDS Society, 2018, 21, e25110.	3.0	96
28	The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. Journal of Infectious Diseases, 2017, 216, 1205-1209.	4.0	28
29	Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. Emerging Infectious Diseases, 2016, 22, 18-23.	4.3	20
30	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases, 2016, 22, 1732-1740.	4.3	77
31	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer, 2016, 139, 510-517.	5.1	19
32	Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions. American Journal of Epidemiology, 2016, 184, 873-883.	3.4	15
33	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	10.0	210
34	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health, The, 2016, 1, e66-e75.	10.0	37
35	Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. Journal of Infectious Diseases, 2016, 214, 685-688.	4.0	37
36	Effect of HPV on cervical cancer screening in Alberta. Cmaj, 2016, 188, 1035.1-1035.	2.0	2

#	Article	IF	Citations
37	Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada. Vaccine, 2016, 34, 1874-1880.	3.8	15
38	Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Journal of the National Cancer Institute, 2016, 108, djv282.	6.3	74
39	Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. Journal of Infectious Diseases, 2016, 213, 1694-1700.	4.0	32
40	Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review. PLoS ONE, 2016, 11, e0163880.	2.5	24
41	Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ, The, 2015, 350, g7584-g7584.	6.0	62
42	Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 276-285.	2.5	15
43	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2015, 15, 565-580.	9.1	556
44	Fewer than three doses of HPV vaccine. Lancet Oncology, The, 2015, 16, e423-e424.	10.7	5
45	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine, 2014, 32, 5845-5853.	3.8	49
46	Potential costâ€effectiveness of the nonavalent human papillomavirus (HPV) vaccine. International Journal of Cancer, 2014, 134, 2264-2268.	5.1	72
47	Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. Vaccine, 2014, 32, 3237-3242.	3.8	21
48	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. The Lancet Global Health, 2014, 2, e406-e414.	6.3	194
49	Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine, 2013, 31, 3863-3871.	3.8	43
50	Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Medicine, 2013, 11, 23.	5.5	24
51	Response. Journal of the National Cancer Institute, 2013, 105, 750-751.	6.3	1
52	Response. Journal of the National Cancer Institute, 2013, 105, 664-665.	6.3	1
53	Inequalities in Human Papillomavirus (HPV)â€“Associated Cancers: Implications for the Success of HPV Vaccination. Journal of the National Cancer Institute, 2013, 105, 158-161.	6.3	23
54	Sociodemographic Inequalities in Sexual Activity and Cervical Cancer Screening: Implications for the Success of Human Papillomavirus Vaccination. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 641-652.	2.5	30

#	Article	IF	Citations
55	Vaccination against herpes zoster in developed countries. Human Vaccines and Immunotherapeutics, 2013, 9, 1177-1184.	3.3	25
56	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. PLoS ONE, 2013, 8, e67072.	2.5	5
57	Dynamic Transmission Modeling. Medical Decision Making, 2012, 32, 712-721.	2.4	117
58	Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine, 2012, 30, 2047-2050.	3.8	43
59	Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value in Health, 2012, 15, 828-834.	0.3	152
60	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 781-789.	9.1	343
61	Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Modelâ€“Based Analysis. Journal of the National Cancer Institute, 2012, 104, 1712-1723.	6.3	119
62	The psychosocial impact of an abnormal cervical smear result. Psycho-Oncology, 2012, 21, 1071-1081.	2.3	80
63	Modelling the Epidemiology of Infectious Diseases for Decision Analysis. Pharmacoeconomics, 2011, 29, 371-386.	3.3	95
64	Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models. Medical Decision Making, 2011, 31, 675-692.	2.4	115
65	Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. European Journal of Pain, 2011, 15, 1100-1106.	2.8	20
66	The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study. Sexually Transmitted Diseases, 2011, 38, 949-956.	1.7	68
67	Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. Journal of Infectious Diseases, 2011, 204, 372-376.	4.0	110
68	Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sexually Transmitted Infections, 2011, 87, 41-43.	1.9	27
69	Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sexually Transmitted Infections, 2011, 87, 209-215.	1.9	22
70	HEALTH-RELATED QUALITY OF LIFE LOST TO ROTAVIRUS-ASSOCIATED GASTROENTERITIS IN CHILDREN AND THEIR PARENTS. Pediatric Infectious Disease Journal, 2010, 29, 73-75.	2.0	59
71	The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Cmaj, 2010, 182, 1731-1736.	2.0	230
72	Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine, 2010, 28, 3385-3397.	3.8	83

#	Article	IF	Citations
73	Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine, 2010, 28, 5473-5484.	3.8	79
74	Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study. Journal of Pain, 2010, 11, 1211-1221.	1.4	106
75	A Prospective Study of the Herpes Zoster Severity of Illness. Clinical Journal of Pain, 2010, 26, 656-666.	1.9	71
76	Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries. Public Health Genomics, 2009, 12, 343-351.	1.0	95
77	Prevalence and type distribution of human papillomavirus in 5,000 British Columbia womenâ€"implications for vaccination. Cancer Causes and Control, 2009, 20, 1387-1396.	1.8	35
78	Modeling Cervical Cancer Prevention in Developed Countries. Vaccine, 2008, 26, K76-K86.	3.8	102
79	The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin, 2008, 4, 238-245.	2.4	81
80	Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective Community-Based Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 397-404.	1.9	36
81	Estimating the Number Needed to Vaccinate to Prevent Herpes Zoster-related Disease, Health Care Resource Use and Mortality. Canadian Journal of Public Health, 2008, 99, 383-386.	2.3	20
82	Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. Cmaj, 2007, 177, 464-468.	2.0	51
83	Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty. American Journal of Epidemiology, 2007, 165, 762-775.	3.4	102
84	Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Clinical Infectious Diseases, 2007, 45, 1527-1529.	5.8	23
85	The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine, 2007, 25, 5399-5408.	3.8	161
86	Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine, 2007, 25, 8326-8337.	3.8	125
87	Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Australian and New Zealand Journal of Public Health, 2005, 29, 544-551.	1.8	44
88	Varicella Vaccine and Shingles. JAMA - Journal of the American Medical Association, 2002, 287, 2211-2212.	7.4	34